CeriBell, Inc. (CBLL)
| Market Cap | 702.76M |
| Revenue (ttm) | 89.06M |
| Net Income (ttm) | -53.41M |
| Shares Out | 37.64M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 382,683 |
| Open | 19.20 |
| Previous Close | 19.39 |
| Day's Range | 18.04 - 19.29 |
| 52-Week Range | 10.01 - 25.37 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 24.67 (+32.14%) |
| Earnings Date | Feb 24, 2026 |
About CBLL
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote acc... [Read more]
Financial Performance
In 2025, CeriBell's revenue was $89.06 million, an increase of 36.09% compared to the previous year's $65.44 million. Losses were -$53.41 million, 32.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CBLL stock is "Strong Buy." The 12-month stock price target is $24.67, which is an increase of 32.14% from the latest price.
News
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in Upcoming March Investor Conferences
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures Becomes th...
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
SUNNYVALE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
CeriBell, Inc. (CBLL) Q3 2025 Earnings Call Transcript
CeriBell, Inc. ( CBLL) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Xingjuan Chao - Co-Founder, President, CEO & Director Scott Blumberg - Chief Financial Officer Conferenc...
Ceribell Reports Third Quarter 2025 Financial Results
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies Accomplished innovator and healthcare executive brings prov...
CeriBell, Inc. (CBLL) Q2 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Scott Blumberg - Chief Financial Officer Xingjuan Chao - Co-Founder, President, CEO & Dire...
Ceribell Reports Second Quarter 2025 Financial Results
SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025
SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EE...
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serio...
CeriBell, Inc. (CBLL) Q1 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Xingjuan Chao - Co-Founder and Chief Executive Officer Scott Blumberg - Chief Financial Offic...
Ceribell Reports First Quarter 2025 Financial Results
SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serio...
Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ser...
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Departmen...
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ser...